Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Rational for HER3-targeting in NRG1 fusion-positive NSCLC

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explains the rational for targeting HER3 in neuregulin 1 (NRG1) fusion-positive non-small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.